Sahin Serkan, Yuce Murat, Alacam Hasan, Karabekiroglu Koray, Say Gokce Nur, Salıs Osman
Child and Adolescent Psychiatry Clinic, Balıkesir Atatürk State Hospital , Balikesir , Turkey.
Int J Psychiatry Clin Pract. 2014 Oct;18(4):280-7. doi: 10.3109/13651501.2014.940054. Epub 2014 Sep 16.
We aimed to explore whether the use of methylphenidate relates leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor (BDNF). In addition, the relationship between methylphenidate-related weight loss in attention deficit hyperactivity disorder (ADHD) patients and these biomolecules were evaluated.
Thirty ADHD patients receiving methylphenidate and 20 healthy controls were included. Leptin, ghrelin, adiponectin, and BDNF levels were measured at baseline and after two-month treatment in both groups.
At baseline, leptin, ghrelin, adiponectin, and BDNF levels were similar in the ADHD and control groups. The most common adverse events occurring in the ADHD group after a 2-month treatment period included loss of appetite (70%) and weight loss (66.7%). A significant difference was found in body weight, BMI, and CGI scores of the ADHD patients after the treatment. While post-treatment ghrelin and adiponectin levels were significantly higher in the ADHD group, BDNF level was significantly lower. Post-treatment decrease in leptin levels was not significant.
Leptin and BDNF were not associated with poor appetite and/or weight loss due to methylphenidate treatment. However, ghrelin and adiponectin might be biomolecules that play a role in underlying neurobiological mechanisms of methylphenidate-related appetite or weight loss.
我们旨在探讨使用哌甲酯是否与瘦素、胃饥饿素、脂联素和脑源性神经营养因子（BDNF）有关。此外，还评估了哌甲酯相关的注意力缺陷多动障碍（ADHD）患者体重减轻与这些生物分子之间的关系。
纳入30例接受哌甲酯治疗的ADHD患者和20例健康对照。在两组的基线期和治疗两个月后测量瘦素、胃饥饿素、脂联素和BDNF水平。
在基线期，ADHD组和对照组的瘦素、胃饥饿素、脂联素和BDNF水平相似。ADHD组在2个月治疗期后出现的最常见不良事件包括食欲减退（70%）和体重减轻（66.7%）。治疗后ADHD患者的体重、BMI和CGI评分有显著差异。治疗后ADHD组的胃饥饿素和脂联素水平显著升高，而BDNF水平显著降低。治疗后瘦素水平的下降不显著。
瘦素和BDNF与哌甲酯治疗导致的食欲减退和/或体重减轻无关。然而，胃饥饿素和脂联素可能是在哌甲酯相关食欲或体重减轻的潜在神经生物学机制中起作用的生物分子。
